Today, CELLINK is announcing the second phase of a multiphase bioink expansion. This second phase includes the announcement of one new bioink-product line and the expansion of three existing series. With this launch, we will continue to grow our product portfolio and offer a wider range of tools for researchers around the world to use in their research. Additional phases of the initiative will be announced soon but will continue to expand our offerings to best serve the needs of our collaborators.  

The New Product Line: GelXA and GelXG 

GelMA is a popular and commonly used bioink within the bioprinting field. At CELLINK we aim to constantly improve our offers in this critical area. We are proud to introduce our GelXA and GelXG line. This bioink line contains our new patent pending thickener based on Xanthan gum, and alginate in the case of GelXA, allowing an even smoother GelMA bioprinting process. Printable and cross-linkable at room temperature, the GelXA and GelXG product line will revolutionize the GelMA research in its ease of use and flexibility in every scientists’ research.

Expansion of START-series:

Prototyping of the size, shape, and geometry of bioprinted constructs remain critical in the field. Addressing the market gap for stable non-biologic but hydrated and cell compatible construct components that can support, protect, and supplement a bioprinted construct we are expanding our START-series to include a crosslinkable variation.  This novel composition can be crosslinked to impart tailorable mechanical properties for print surfaces and stability during culture for softer or mechanical weak biomaterials. Additionally, it can serve as a standardized bioink for geometrical or printability comparison.  

Expansion of the Fibrin, Skin, Laminin, and Bone Line

We are happy to expand our existing Fibrin, Skin, Laminink, and Bone series to be comprised of GelXA as the base material. This base material allows the user to choose between using photo initiator assisted or ionic crosslinking, or the combination. We are launching these new bioink compositions to allow greater flexibility for our researchers and their applications. 

For further information, please contact:

Erik Gatenholm, CEO                                                   Gusten Danielsson, CFO

Phone: +46 73 267 00 00                                             Phone: +46 70 991 86 04

E-mail:[email protected]                                                 E-mail:[email protected] 


CELLINK has created one of the world's first universal Bioinks, today used by many of the world's most wellreputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. CELLINK is listed at Nasdaq First North with the ticker CLNK. Erik Penser Bank AB, tel: +46 8 463 80 00, is the Company's Certified Adviser.

Latest press releases